Browsing Tag
VHB937
1 post
Novartis drops ALS drug lifonebart after Phase 2 trial misses key goals
Novartis has discontinued development of VHB937, or lifonebart, in amyotrophic lateral sclerosis after a 251-patient Phase 2 trial missed its primary and secondary objectives, adding to several recent pipeline disappointments.